SOURCE: Mitogenetics


February 05, 2015 17:33 ET

Mitogenetics Chosen as a Presenter at the New York Innovation Showcase

Event Is Aimed to Spearhead Innovation Growth in New York State

OLD WESTBURY, NY--(Marketwired - Feb 5, 2015) - Mitogenetics, LLC, a research and development company focused on creating products that will allow people to live healthier, longer lives, has been chosen to present at the New York Innovation Showcase at the SUNY Global Center, located at 116 E. 55th St., on Thursday, February 12.

The showcase brings together some of the best innovation-based early-stage companies from across New York state and connects them with angels, venture capitalists and industry investors. Support for innovation and entrepreneurship is a key pillar of New York Governor Andrew Cuomo's administration and is part of an ambitious innovation agenda to help speed good ideas to market and grow innovation clusters in the region.

Mitogenetics is focused on the research, development and refinement of biomedical technology, in particular primordial energy control and signaling systems regulating mitochondrial metabolism. Diseases that have been linked to mitochondrial dysfunction include Type II diabetes, obesity, eating disorders, cardiovascular disease, hypertension and neurodegenerative disorders like Alzheimer's disease and Parkinson's disease. The Mitogenetics team is led by Dr. George Stefano, whose laboratory facilities are at the State University of New York at Old Westbury.

"Our research projects have the chance to lead to major breakthroughs in therapeutic strategies for mitochondrial dysfunction," said Marcia Hendrickson, President and CEO of Mitogenetics. "The goal is to control mitochondrial energy balance via natural processes and dietary compounds for medicinal remedies and produce commercially viable products for human, plant and animal health."

For information, go to

About Mitogenetics
Mitogenetics, LLC was founded in 2010 by Dr. William P. Switzer, DVM, PhD, Dr. h.c. The company's research projects are leading to major breakthroughs in therapeutic strategies in human diseases disorders that have been functionally linked to cellular mitochondrial dysfunction and pursuing research that will produce commercially viable products for human, plant and animal health.

Mitogenetics is operated by the Val-Add Corporation, a Sioux Falls, S.D., management firm that in the last several years has assisted in the development of more than 20 ethanol plants in eight states, as well as working with projects as diverse as biodiesel production, soybean crushing, egg-laying, beef processing, fish farming and dairy production.

Contact Information